KYGEVVI

Launch

doxecitine and doxribtimine

UCB Pharma
NDAORALFOR SOLUTIONPriority Review
Approved
Nov 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
1

Mechanism of Action

nucleosides, deoxycytidine and deoxythymidine, into skeletal muscle mitochondrial deoxyribonucleic acid (DNA). This action restores mitochondrial DNA copy number in TK2d mutant mice.

Indications (2)

thymidine kinase 2 deficiency (TK2d) in adultsbefore 12 years

Clinical Trials (1)

NCT06590493N/AAvailable

Doxecitine and Doxribtimine-Expanded Access

Thymine Kinase 2 Deficiency

Loss of Exclusivity

LOE Date
Aug 19, 2040
176 months away
Patent Expiry
Aug 19, 2040
Exclusivity Expiry
Nov 3, 2030

Patent Records (2)

Patent #ExpiryTypeUse Code
10471087
Aug 7, 2036
U-4358
11649259
Aug 19, 2040
Product
U-4358
Company
UP
UCB Pharma
Belgium - Brussels
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers